DE-EDCP

04/01/2019 - "Toxicity study of DE-EDCP as a potential drug for cancer therapy: Toxicity profile of DE-EDCP."
06/15/2018 - "In conclusion, DE-EDCP impairs breast cancer growth and progression by triggering cancer cell death and inhibition of cancer cell proliferation. "
06/15/2018 - "It has been noticed that new organic ester ligand, O,O'-diethyl-(S,S)-ethylenediamine-N,N'-di-2-(3-cyclohexyl)propanoate dihydrochloride (named DE-EDCP) showed effective cytotoxic capacities against several human and mouse cancer cell lines. "
04/01/2019 - "It was reported that novel O, O'-diethyl-(S, S)-ethylenediamine- N, N'-di-2-(3-cyclohexyl) propanoate dihydrochloride (DE-EDCP) displayed in vitro antiproliferative activity on several human and mouse cancer cell lines, which was comparable to that of the prototypical anticancer drug cisplatin. "

06/15/2018 - "The aim of present study was to examine the ability of DE-EDCP to inhibit 4T1 murine breast cancer growth and progression and to explore possible molecular mechanisms. "
06/15/2018 - "DE-EDCP treatment increased the percentage of TUNEL-positive nuclei and reduced Ki-67 expression in breast cancer tissue. "
06/15/2018 - "Further, marked reduction of murine breast cancer growth and progression by DE-EDCP was shown. "
06/15/2018 - "DE-EDCP exhibited significant tumoricidal activity on human and murine breast cancer cell lines. "
06/15/2018 - "In conclusion, DE-EDCP impairs breast cancer growth and progression by triggering cancer cell death and inhibition of cancer cell proliferation. "

04/01/2019 - "The intravenous LD50 values of DE-EDCP were found to be 95.3 and 101.3 mg/kg body weight in female and male mice, respectively. "